Vera Therapeutics Inc. (Class A) (VERA) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Vera Therapeutics Inc. (Class A) (NASDAQ: VERA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $30.25 (-2.36% 1D, market cap $2.23B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VERA ranks #749 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XNCR (Xencor Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B) and AUPH (Aurinia Pharmaceuticals Inc) posts a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
Per VERA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831828), Vera Therapeutics Inc. (Class A) generated $883.3M in revenue (+88.7% YoY), -$299.6M in net income, and -$241.7M in free cash flow against $734.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While VERA currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($31.91) and Max Pain ($31.76) forces dealer call-delta covering toward $58.85.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Vera Therapeutics Inc. (Class A) (VERA) dropped -2.36% to $30.25, trading at 22% of its 52-week range ($23.05 – $56.05). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
BRISBANE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that the Company’s management team will participate in a fireside chat
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in composi
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +88.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on VERA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for VERA. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Vera Therapeutics Inc. (Class A) (VERA) ranks #749 by composite RQD confidence (31/100, grade E) and #237 by equity capitalization ($2.23B). Within this direct 5-issuer industry benchmark cohort, AUPH leads on earnings valuation at 8.0x trailing P/E, while HRMY leads on capital efficiency and profitability with 63.0% ROIC and 77.2% gross margin. HRMY currently holds the highest overall quantitative score in the immediate peer group at 86/100 (A) compared with VERA at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VERA
ACTIVE
Vera Therapeutics Inc. (Class A) | E | 31/100 | — | — | -35.0% | -2.36% | $2.23B | Benchmark Subject |
| XNCR Xencor Inc. | D | 47/100 | — | — | -21.3% | -0.54% | $2.22B | /xncr-vs-vera → |
| AUPH Aurinia Pharmaceuticals Inc | B | 74/100 | 8.0x | 88.5% | 16.5% | -3.06% | $2.22B | /auph-vs-vera → |
| HRMY Harmony Biosciences Holdings Inc. | A | 86/100 | 14.2x | 77.2% | 63.0% | -2.19% | $2.26B | /hrmy-vs-vera → |
| PRGO Perrigo Company plc | D | 49/100 | — | 35.1% | -13.6% | -0.19% | $2.19B | /prgo-vs-vera → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vera Therapeutics Inc. (Class A) (VERA) reported GAAP revenue of $883.3M (+88.7% vs. FY2024 revenue of $468.1M , and +209.3% cumulative change since FY2023) , GAAP net income of -$299.6M, operating cash flow of -$241.1M, and free cash flow of -$241.7M (-78.2% YoY). On the balance sheet, VERA closed FY2025 with $734.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $883.3M | -$299.6M | -$241.1M | -$241.7M | $734.7M | — |
| FY2024 (FY) | 2024-12-31 | $468.1M | -$152.1M | -$134.7M | -$135.7M | $655.7M | — |
| FY2023 (FY) | 2023-12-31 | $285.6M | -$96.0M | -$92.2M | -$92.2M | — | — |
As of 2026-11-03, Vera Therapeutics Inc. (Class A) (NASDAQ: VERA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $30.25 (-2.36% 1D, market cap $2.23B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, VERA ranks #749 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VERA carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, XNCR (Xencor Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -21.3%, cap $2.22B) and AUPH (Aurinia Pharmaceuticals Inc) posts a B grade (74/100 RQD, P/E 8.0x, ROIC 16.5%, cap $2.22B). Among the 5-stock peer group, AUPH leads on earnings multiple (8.0x) while HRMY leads on capital efficiency (63.0% ROIC).
Per VERA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001831828), Vera Therapeutics Inc. (Class A) generated $883.3M in revenue (+88.7% YoY), -$299.6M in net income, and -$241.7M in free cash flow against $734.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
VERA last traded at $30.25 (-2.36% on volume of 2,111,205 shares), positioning the stock -5.20% below its 50-day simple moving average ($31.91) and -17.80% below its 200-day simple moving average ($36.80). Across its 52-week range of $23.05 to $56.05, VERA sits at the 21.8% percentile with a 14-day RSI of 52.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.2% ($26.86 to $33.64).
Vera Therapeutics Inc. (Class A) (VERA) earns a live Roarable RQD composite score of 31/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $30.25 (-2.36% 1D, market capitalization $2.23B).
Vera Therapeutics Inc. (Class A) (VERA) is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations..2B. Revenue is reported as — across the available periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vera Therapeutics Inc. (Class A) (VERA) reported $883.3M in annual revenue (up from $468.1M in FY2024, +88.7% YoY) and -$299.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($285.6M revenue, -$96.0M net income) through FY2025, VERA scaled operating cash flow to -$241.1M and free cash flow to -$241.7M, backed by $734.7M in total assets against $0 in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), VERA carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Vera Therapeutics Inc. (Class A) (VERA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Vera Therapeutics Inc. (Class A) (VERA) market action, institutional positioning, and fundamental catalysts.
Long VERA at $30.98 targeting $40.89. Positive FDA approval and Phase III IgA nephropathy results, with Raymond James reiterating a Strong Buy, support the near-term catalyst narrative.. Institutional whale score is 6/20 and the risk/reward vs. the $23.05 52-week low is skewed heavily in favor of bulls.
@BreakoutHunter Agree on the RQD 31/100 quality, though with 1.0 beta I'm scaling in with half-size at $30.98 and keeping dry powder in case we test $28.81.
I respect the product at Vera Therapeutics Inc. (Class A), but the stock at $30.98 is a different story. Negative ROIC of -35%, free cash flow of -$241.7M in FY 2025, and an F-Score of 2/9 sit against a $2.2B market capitalization.. FCF yield is -10.99% and RQD sits at 31/100 (E) — why pay up here when you can wait for next quarter's numbers?
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).